Gene-Targeted ADHD drug shows promise in small early trial
NCT ID NCT02286817
First seen Nov 01, 2025 · Last updated Apr 29, 2026 · Updated 35 times
Summary
This early-stage study tested a new drug called NFC-1 in 30 teenagers aged 12-17 with ADHD who also have certain gene changes. The goal was to see if the drug is safe and how it affects ADHD symptoms over four weeks. Researchers measured side effects, drug levels in the blood, and changes in ADHD rating scales.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ATTENTION-DEFICIT/ HYPERACTIVITY DISORDER (ADHD) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Thomas Jefferson University, Clinical Research Unit
Philadelphia, Pennsylvania, 19107, United States
Conditions
Explore the condition pages connected to this study.